Home » Stocks » Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc. (ARPO)

Stock Price: $1.28 USD -0.06 (-4.48%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $1.39 +0.11 (8.59%) Oct 26, 4:47 PM

Stock Price Chart

Key Info

Market Cap 53.85M
Revenue (ttm) 15.00M
Net Income (ttm) -3.74M
Shares Out 42.07M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $1.28
Previous Close $1.34
Change ($) -0.06
Change (%) -4.48%
Day's Open 1.34
Day's Range 1.25 - 1.36
Day's Volume 3,167,823
52-Week Range 0.42 - 1.90

More Stats

Market Cap 53.85M
Enterprise Value 9.08M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 42.07M
Float 34.41M
EPS (basic) -0.09
EPS (diluted) -0.09
FCF / Share -0.08
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.47M
Short Ratio 1.00
Short % of Float 4.27%
Beta 1.96
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.59
PB Ratio 1.32
Revenue 15.00M
Operating Income -4.48M
Net Income -3.74M
Free Cash Flow -3.29M
Net Cash 44.76M
Net Cash / Share 1.06
Gross Margin 100.00%
Operating Margin -29.89%
Profit Margin -24.90%
FCF Margin -21.95%
ROA -4.64%
ROE -8.46%
ROIC 233.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

Current: $1.28
Target: 2.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-20.16---
Operating Income-24.44-11.18-21.39-16.63-0.02
Net Income-23.27-10.40-21.40-16.98-0.03
Shares Outstanding40.5933.9321.670.855.00
Earnings Per Share-0.57-0.31-1.03-24.52-0.01
Operating Cash Flow-23.85-5.81-18.88-15.72-0.02
Capital Expenditures-0.24-0.04-0.01-0.11-
Free Cash Flow-24.09-5.85-18.89-15.83-0.02
Cash & Equivalents38.5662.6520.291.680.02
Total Debt0.17--12.390.16
Net Cash / Debt38.3962.6520.29-10.71-0.14
Book Value36.5458.6717.44-86.22-0.19
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aerpio Pharmaceuticals, Inc.
Country United States
Employees 12
CEO Joseph H. Gardner

Stock Information

Ticker Symbol ARPO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARPO


Aerpio Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.